Emmaus Life Sciences, Inc. (EMMA)
| Previous Close | 0.0000 |
| Open | 0.0399 |
| Bid | 0.0200 x 0 |
| Ask | 0.0380 x 0 |
| Day's Range | 0.0399 - 0.0399 |
| 52 Week Range | 0.0001 - 0.1350 |
| Volume | |
| Avg. Volume | 38,923 |
| Market Cap | 1.105M |
| Beta (5Y Monthly) | 6.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireEmmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.
- PR Newswire
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
Emmaus Life Sciences, Inc. (OTCMarkets: EMMA), a leader in sickle cell disease treatment, announced that Willis C. Lee has been appointed as Chief Executive Officer. Mr. Lee, who previously served as Co-President and Chief Operating Officer, will continue to serve as Chairman of the Board.
- PR Newswire
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.
